Skip to main content

Table 1 Demographic and clinical characteristics of all participants

From: Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease

  NAFLD cases Controls P value
Age (years) 49.40 ± 12.01 45.66 ± 10.33 0.140
Sex
 Male 13 (32.50%) 21 (52.50%) 0.070
 Female 27 (67.50%) 19 (47.50%)
Special habits
 Non-smoker 30 (75.00%) 32 (80.00%) 0.592
 Smoker 10 (25.00%) 8 (20.00%)
Hypertension
 No 25 (62.5%) 40 (100%) < 0.001
 Yes 15 (37.5%) 0 (0.00%)
Weight (kg) 93.96 ± 12.64 72.02 ± 7.37 < 0.001
Height (cm) 165.16 ± 4.69 167.50 ± 6.67 0.074
Body mass index 34.31 ± 4.03 25.70 ± 2.53 < 0.001
Waist (cm) 98.10 ± 10.76 78.12 ± 4.65 < 0.001
Interleukin 32 serum levels (pg/mL) 76 (45.5-111.125) 13 (8-15) < 0.001
Aspartate aminotransferase IU/L 52.05 ± 12.44 28.72 ± 5.58 < 0.001
Alanine aminotransferase IU/L 60.35 ± 16.92 33.17 ± 4.42 < 0.001
Total bilirubin mg/dL 0.67 ± 0.29 0.72 ± 0.26 0.451
Albumin g/dL 3.55 ± 0.42 4.26 ± 0.45 < 0.001
Total glycerides mg/dL 210.85 ± 23.74 131.80 ± 14.60 < 0.001
Total cholesterol mg/dL 230.32 ± 25.97 170.70 ± 17.53 < 0.001
High-density lipoprotein mg/dL 29.17 ± 3.56 37.15 ± 6.26 < 0.001
Low-density lipoprotein mg/dL 160.65 ± 25.93 106.25 ± 19.03 < 0.001
  1. Variables were shown as frequency and percentages for categorical variables, mean and standard deviation for parametric numerical variables, and median (interquartile range) for non-parametric numerical variables